Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany
Authors:
- Charalabos-Markos DintsiosCDCharalabos-Markos Dintsios
- Alexander HaverkampAHAlexander Haverkamp
- Johannes WiegandJWJohannes Wiegand
- Tilman GerlachTGTilman Gerlach
- Heiner WedemeyerHWHeiner Wedemeyer
- Gerd PapeGPGerd Pape
- Michael Peter MannsMMMichael Peter Manns
- Christian KrauthCKChristian Krauth
- 1 March 2010
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 22 (3) , 278-288
Abstract
Antiviral treatment of acute hepatitis C virus (HCV) almost doubles the chance of sustained virological response (SVR) compared with that achievable by treating chronic HCV. To conduct a health economic evaluation comparing early and delayed therapies for acute HCV in Germany. One hundred and thirty-three patients with acute HCV were evaluated in two early monotherapy (EMT) studies and 60 in a delayed therapy study. Efficacy was determined by SVR. In the EMT studies, patients were treated with either standard or pegylated interferon for 24 weeks. In the delayed therapy study, patients with persisting infection were treated with interferon monotherapy or combination therapy with ribavirin for a median of 36 weeks. We conducted a cost-effectiveness analysis based on the study results and a linear simulation model based on current treatment recommendations. The SVR rate for the sex-adjusted on-treatment analysis between early and delayed therapies was not significantly different (92.7 vs. 90.9%; P = 0.7). Medication costs accounted for more than 90% in both treatment options. Direct medical costs of early therapy (€7064/patient) were €321 lower than those of delayed therapy (P = 0.8). The incremental cost-effectiveness ratio was −178 €/SVR(%) (confidence interval: −224 to 360 €/SVR(%)). Average modeled direct medical costs of delayed combination therapy were from €6745 to €8299 per patient (from approximately 7% less up to 15% higher than EMT). Spontaneous viral clearance and therapy duration were the most sensitive variables. There was no significant efficacy and cost difference between therapy alternatives in base cases. However, in the majority of scenarios in the sensitivity analyses, EMT was a more cost-effective option in acute HCV therapy.Keywords
This publication has 48 references indexed in Scilit:
- Prevalence of hepatitis C in a German prison for young men in relation to country of birthEpidemiology and Infection, 2006
- Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic ResponseGastroenterology, 2006
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in GermanyThe European Journal of Health Economics, 2005
- Efficacy of a 24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearanceJournal of Hepatology, 2005
- When and how to treat acute hepatitis C?Journal of Hepatology, 2003
- Treatment of Acute Hepatitis C with Interferon Alfa-2bNew England Journal of Medicine, 2001
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parametersJournal of Hepatology, 1997
- High-dose interferon-α2b treatment prevents chronicity in acute hepatitis CDigestive Diseases and Sciences, 1996